KRRO · Korro Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $1.46M | $0 | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $12.95M | - | $13.82M | $21.03M | $19.74M | - | $15.96M | $17.14M | $13.57M | - |
| SG&A | $7.49M | - | $6.51M | $7.63M | $7.83M | - | $7.33M | $6.99M | $7.88M | - |
| Total Operating Expenses | $20.44M | - | $20.33M | $28.66M | $27.57M | - | $23.29M | $24.13M | $21.45M | - |
| D&A | $380.0K | - | $1.20M | $1.20M | $1.23M | - | - | - | $726.0K | - |
| Operating Income | ($20.44M) | - | ($19.24M) | ($27.20M) | ($25.02M) | - | ($23.29M) | ($24.13M) | ($21.45M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $95.0K | - | $0 | $1.0K | $0 | - | ($9.0K) | $30.0K | $17.0K | - |
| Net Income | ($19.63M) | - | ($18.06M) | ($25.77M) | ($23.39M) | - | ($21.00M) | ($21.83M) | ($19.56M) | - |
| EPS - Basic | ($1.69) | - | ($1.92) | ($2.74) | ($2.49) | - | ($2.26) | ($63.83) | ($2.44) | - |
| EPS - Diluted | ($1.69) | - | ($1.92) | ($2.74) | ($2.49) | - | ($2.26) | ($2.43) | ($2.44) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61.70M | $21.82M | $24.16M | $33.61M | $64.14M | $55.64M | $63.21M | $91.15M | $138.80M | $166.15M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.96M | $1.65M | $2.30M | $5.16M | $4.18M | $3.99M | $5.95M | $5.69M | $4.66M | $7.28M |
| Current Assets | $120.16M | $82.37M | $98.23M | $102.63M | $121.23M | $131.53M | $152.78M | $163.63M | $145.66M | $172.73M |
| Total Assets | $183.62M | $113.51M | $161.55M | $180.43M | $202.21M | $226.24M | $243.54M | $249.59M | $197.99M | $221.66M |
| Current Liabilities | $14.79M | $11.94M | $14.64M | $17.17M | $12.88M | $14.96M | $13.61M | $12.32M | $11.05M | $19.48M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $63.99M | $62.07M | $62.52M | $65.32M | $63.25M | $65.83M | $63.91M | $51.51M | $46.63M | $51.75M |
| Stockholders' Equity | $119.63M | $51.44M | $99.03M | $115.10M | $138.96M | $160.41M | $179.63M | $198.08M | $151.36M | $169.91M |
| Retained Earnings | ($403.47M) | ($383.85M) | ($333.80M) | ($315.74M) | ($289.97M) | ($266.59M) | ($245.39M) | ($224.39M) | ($202.56M) | ($183.00M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.07M) | - | - | - | ($24.45M) | - | - | - | ($21.89M) | - |
| Investing Cash Flow | ($32.24M) | - | - | - | $32.78M | - | - | - | ($5.61M) | - |
| Financing Cash Flow | $88.21M | - | - | - | $172.0K | - | - | - | $139.0K | - |
| CapEx | $21.0K | - | - | - | $119.0K | - | - | - | $5.61M | - |
| Free Cash Flow | ($16.09M) | - | - | - | ($24.57M) | - | - | - | ($27.50M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -1863.2% | - | - | - | - | - | - |
| EBITDA margin | - | - | - | -1781.0% | - | - | - | - | - | - |
| Net margin | - | - | - | -1765.1% | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.82 | - | - | - | 1.05 | - | - | - | 1.41 | - |
| R&D / Revenue | - | - | - | 1440.5% | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | 522.7% | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.7% | - | -11.2% | -14.3% | -11.6% | - | -8.6% | -8.7% | -9.9% | - |
| Return on equity | -16.4% | - | -18.2% | -22.4% | -16.8% | - | -11.7% | -11.0% | -12.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.13 | 6.90 | 6.71 | 5.98 | 9.41 | 8.79 | 11.23 | 13.28 | 13.18 | 8.87 |
| Quick ratio | 8.13 | 6.90 | 6.71 | 5.98 | 9.41 | 8.79 | 11.23 | 13.28 | 13.18 | 8.87 |
| Cash ratio | 4.17 | 1.83 | 1.65 | 1.96 | 4.98 | 3.72 | 4.64 | 7.40 | 12.56 | 8.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.53 | 2.21 | 1.63 | 1.57 | 1.46 | 1.41 | 1.36 | 1.26 | 1.31 | 1.30 |
| Liabilities / Assets | 0.35 | 0.55 | 0.39 | 0.36 | 0.31 | 0.29 | 0.26 | 0.21 | 0.24 | 0.23 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.01 | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.1x | - | 4.5x | 1.0x | 1.2x | - | 1.7x | 0.0x | 4.8x | - |
| P / S | - | - | - | 80.3x | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | -29.7% | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 18.3% | - | 17.4% | -12.8% | -16.6% | - | -83.9% | -103.9% | -4.6% | - |
| Net income growth (YoY) | 16.1% | - | 14.0% | -18.1% | -19.6% | - | -80.8% | -102.2% | -0.1% | - |
| EPS growth (YoY) | 32.1% | - | 15.0% | -12.8% | -2.0% | - | -629.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 34.5% | - | - | - | 10.7% | - | - | - | -93.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -13.9% | -67.9% | -44.9% | -41.9% | -8.2% | -5.6% | 389.0% | 336.2% | 184.2% | 145.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Korro Bio against the 5 most active filers in the same SIC group.